The Lancet Gastroenterology & Hepatology
LightNews LightNews
banner
lancetgastrohep.bsky.social
The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social
980 followers 77 following 160 posts
The Lancet Gastroenterology & Hepatology is the world-leading #gastroenterology and #hepatology research journal. IF=38.6.

🌐 thelancet.com/journals/langas/home
Posts Replies Media Videos
Pinned
lancetgastrohep.bsky.social
The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · Jul 3
We are the world-leading journal dedicated to gastroenterology & hepatology research and review.

While a partial measurement of our impact, we are pleased to share our 2024 Impact Factor is 38·6 and our CiteScore is 51·1.

hubs.li/Q03v92mL0

#GastroSky #MedSky #LiverSky
Publish with The Lancet Group
hubs.li
lancetgastrohep.bsky.social
New Comment - Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease
Inflammatory bowel disease (IBD) has expanded beyond its initial confines of early industrialised countries in North America, Europe, and Oceania and now constitutes a global illness. Once rare in the...
www.thelancet.com
November 26, 2025 at 6:00 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancetoncol.bsky.social
🚨Our Dec issue is live! - thelancet.com/issue/S1470-...

📊Articles: #lungcancer, #breastcancer, #hepatocellularcarcinoma, #rectalcancer, #glioma

📑Reviews including neurocognitive outcomes in patients with brain metastases AND SISAQOL-IMI consensus guidelines on PROs in trials
November 25, 2025 at 9:58 AM
lancetgastrohep.bsky.social
New research - Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial
Mirikizumab exhibited safety and efficacy in paediatric participants with moderately-to-severely active ulcerative colitis. These results support further evaluation of mirikizumab in the paediatric po...
www.thelancet.com
November 19, 2025 at 8:21 AM
Reposted by The Lancet Gastroenterology & Hepatology
robbrierley.bsky.social
New research @eClinicalMed - A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #IBDSky
A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities
Treatment efficacy in similar WH and SA IBD patients recruited to the UK IBD BioResource is unaffected by ethnicity but patients from SA ethnic backgrounds are at increased risk of developing pancreat...
www.thelancet.com
November 18, 2025 at 2:33 PM
Reposted by The Lancet Gastroenterology & Hepatology
robbrierley.bsky.social
New @eclinicalmed.bsky.social - Preprocedural screening for multidrug-resistant organisms in endoscopic retrograde cholangiopancreatography: an international, multicentre, cross-sectional observational study

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #IDSky #MicroSky
Preprocedural screening for multidrug-resistant organisms in endoscopic retrograde cholangiopancreatography: an international, multicentre, cross-sectional observational study
This study shows global heterogeneity in MDRO carriage among patients undergoing ERCP, reflecting underlying differences in antimicrobial resistance, healthcare infrastructure, and infection control p...
www.thelancet.com
November 18, 2025 at 2:35 PM
Reposted by The Lancet Gastroenterology & Hepatology
robbrierley.bsky.social
New @eClinicalMed - Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #EndoSky
Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis
GLP-1 RAs, particularly Semaglutide and liraglutide, reduce alcohol use as measured by AUDIT scores and show beneficial effects on consumption, relapse, and alcohol-related morbidity. Mechanistic evid...
www.thelancet.com
November 18, 2025 at 2:36 PM
Reposted by The Lancet Gastroenterology & Hepatology
robbrierley.bsky.social
New at The Lancet Digital Health - Development and validation of a machine-learning model to reduce futile procurements in donations after circulatory death in liver transplantation in the USA: a multicentre study

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Development and validation of a machine-learning model to reduce futile procurements in donations after circulatory death in liver transplantation in the USA: a multicentre study
We show that, compared with surgeon predictions and existing risk-prediction tools, our machine-learning model can enhance the accuracy of the prediction of progression to death in DCD donors and redu...
www.thelancet.com
November 18, 2025 at 2:44 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
Despite their high prevalence, alcohol use disorders remain undertreated.

A recent Seminar discusses the need for integrated alcohol control policies to improve the prevention of alcohol use disorders, improve access to treatment, and reduce stigma: spkl.io/63324Abjiu
Figure: Interaction between different levels of drinking in crisis situations. Copyright: Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
November 11, 2025 at 4:05 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
Liver cancer is the 6th most common cancer globally.

Join our webinar exploring The Lancet's Commission on addressing the global liver cancer burden and its comprehensive strategies from prevention to treatment.

👉 Register: hubs.li/Q03GK-q50

#oncology #hepatology #lgcw2025
Blue graphic promoting a Lancet Webinar. Text saying: "Join Jian Zhou, Professor at Zhongshan Hospital, Fudan University, for our global webinar on global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET". A photograph of Professor Zhou appears on the right-side of the graphic. Copyright: Elsevier Ltd.
November 12, 2025 at 8:17 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
📣 Big news! We’re excited to announce the Advisory Board for The #LancetSummit: shaping the future of #diabetes prevention. Welcome Amanda Adler, Kamlesh Khunti, Dianna Magliano, Chantal Mathieu and Didac Mauricio Puente. Find out more and submit your abstract to join the Summit: hubs.li/Q03MV20T0
The Lancet Summit: shaping the future of diabetes prevention. Image credit: Ixefra / Getty Images.
November 12, 2025 at 9:03 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
🔔 Introducing The Lancet Regional Health – Africa, a new #goldopenaccess journal promoting the advancement of clinical practice and health policy in Africa.

Explore the new journal: ➡️ spkl.io/63325AbmLD #MedSky
A special preview issue of The Lancet Regional Health – Africa. On the cover is a photograph of a doctor examining a Maasai baby. Copyright: Hugh Sitton/Getty Images.
November 12, 2025 at 11:04 AM
lancetgastrohep.bsky.social
New @thelancet.com - Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

www.thelancet.com/journals/lan...

#LiverSky #MedSky #EndoSky
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MAS...
www.thelancet.com
November 12, 2025 at 7:59 AM
Reposted by The Lancet Gastroenterology & Hepatology
lancetmicrobe.bsky.social
Our November issue is now online:

www.thelancet.com/journals/lan...

Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #HTLV-1 #AMR #Lassa #Neisseria #gonorrhoea #tuberculosis #TB #influenza

#IDSky #ClinMicro #OA
Cover of the November issue of The Lancet Microbe
November 8, 2025 at 9:38 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
Endometriosis affects around 190 million women and girls globally. Despite progress, the exact causes remain unknown.

The latest issue of @lancetobgyn-wh.bsky.social features articles on advancements & the research still needed.

🔗 : tinyurl.com/4by2evfs
Alt-text: The cover of The Lancet Obstetrics, Gynaecology, & Women’s Health which features artwork of a woman curled around, holding her abdomen due to pain from endometriosis. The world map is visible in the background. Copyright: Cover image by Elizabeth Sanduvete Chaves.
November 6, 2025 at 1:02 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancetrheum.bsky.social
NEW RESEARCH—IgG4-related disease in the Japanese population: a whole-genome sequencing study bit.ly/4oVaGPm

Plus, linked Comment bit.ly/4hOOOmz
#Medsky #Rheumsky
November 6, 2025 at 3:42 PM
lancetgastrohep.bsky.social
Our December issue is out now at www.thelancet.com/journals/lan...

Content includes diet in GI disorders; IBS; IBD; oesophageal cancer; alcohol-related liver disease; MASLD + more!

#GastroSky #LiverSky #MedSky
November 6, 2025 at 6:57 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
What if we could work together to change the future of liver cancer?

Join our webinar exploring how we can tackle the rising trend of liver cancer and differences in disease management across regions, hosted as part of London Global Cancer Week.

📆 Nov 27, 9am GMT
👉 Register: hubs.li/Q03GK-q50
Blue graphic with text saying: "The Lancet Webinars. Join our global webinar on the global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET. An image of a red liver in a blue body appears on the right of the graphic in a hexagonal frame. Copyright: Elsevier Ltd.
November 3, 2025 at 3:23 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancet.com
Non-coeliac gluten sensitivity (NCGS) remains a highly debated condition, despite ~10% of the global population self-reporting a gluten or wheat sensitivity.

A new Review examines current evidence & provides practical guidance for assessment and management: tinyurl.com/yjafmhc5
Non-coeliac gluten sensitivity
Non-coeliac gluten sensitivity (NCGS) refers to individuals who report intestinal and extraintestinal symptoms related to the ingestion of gluten-based or wheat-based foods, in the absence of coeliac ...
www.thelancet.com
October 30, 2025 at 12:44 PM
Reposted by The Lancet Gastroenterology & Hepatology
thelancetoncol.bsky.social
🚨Our Nov issue is live - thelancet.com/issue/S1470-...

📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma

📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)
October 28, 2025 at 9:39 AM
lancetgastrohep.bsky.social
New research - Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
Cilofexor did not significantly reduce the rate of fibrosis progression (vs placebo) in participants with non-cirrhotic PSC. A greater percentage of cilofexor-treated participants had pruritus than pl...
www.thelancet.com
October 29, 2025 at 7:50 AM
lancetgastrohep.bsky.social
New research - Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Linerixibat significantly improved pruritus versus placebo, supporting its potential to address a major symptom of PBC. An expected increase in diarrhoea in linerixibat-treated patients was observed.
www.thelancet.com
October 29, 2025 at 7:49 AM
lancetgastrohep.bsky.social
New research - Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

www.thelancet.com/journals/lan...

#GastroSky #MedSky
October 28, 2025 at 7:25 AM
Reposted by The Lancet Gastroenterology & Hepatology
thelancetrheum.bsky.social
Our November issue is live!

Including research on hip #osteoarthritis, #JIA, #BackPain, and #PsoriaticArthritis, plus much more! thelancet.com/journals/lan...
Cover by Sara Gironi Carnevale #Medsky #Rheumsky
October 21, 2025 at 4:39 PM
lancetgastrohep.bsky.social
New Review - Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases
Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence relat...
www.thelancet.com
October 17, 2025 at 7:55 AM
lancetgastrohep.bsky.social
New research - Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #OncSky
October 16, 2025 at 5:49 AM